Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.
Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.
Over a 2-year period, Nicole M. Ryan, PhD, of The University of Newcastle and John Hunter Hospital in NSW, Australia, and colleagues recruited 62 adult patients with refractory chronic cough lasting longer than 8 weeks from the John Hunter Hospital respiratory outpatient clinic. Patients were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1,800 mg) or matching placebo for 10 weeks.
The researchers noted that gabapentin significantly improved cough-specific quality of life compared with placebo. Ten patients (31%) experienced side effects, the most common being nausea and fatigue compared with 3 patients (10%) in the placebo group.
These positive effects suggest that central reflex sensitization is a relevant mechanism in refractory chronic cough, and that gabapentin might be an effective therapy, the authors wrote.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 5th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 5th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More